CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-04 | Meckler Jeffrey A Director | Sale 10b5-1 | −8,000 | $45.00 | $360K | 87,500 |
| 2026-05-04 | Meckler Jeffrey A Director | Option exercise · Stock option (right to buy) 10b5-1 | −8,000 | 0 | ||
| 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +20,000 | $17.96 | $359K | 125,211 |
| 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −20,000 | $45.00 | $900K | 105,211 |
| 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +4,250 | 109,461 | ||
| 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −20,000 | 0 | ||
| 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | Grant or award · Performance-based restricted stock units 10b5-1 | +8,500 | 8,500 | ||
| 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Performance-based restricted stock units 10b5-1 | −4,250 | 4,250 | ||
| 2026-05-01 | Baynes Roy D. Director | Option exercise 10b5-1 | +9,750 | $6.82 | $66K | 47,250 |
| 2026-05-01 | Baynes Roy D. Director | Sale 10b5-1 | −9,750 | $44.22 | $431K | 37,500 |
| 2026-05-01 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −9,750 | 9,750 | ||
| 2026-04-22 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −9,100 | $39.09 | $356K | 113,987 |
| 2026-04-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,014 | $42.61 | $43K | 116,899 |
| 2026-04-15 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,018 | $42.61 | $43K | 111,473 |
| 2026-04-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −56,815 | $41.01 | $2.3M | 440,071 |
| 2026-04-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −7,165 | $41.75 | $299K | 432,906 |
| 2026-04-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −20 | $42.66 | $853 | 432,886 |
| 2026-04-15 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −5,226 | $41.62 | $218K | 106,770 |
| 2026-04-15 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −1,559 | $42.53 | $66K | 105,211 |
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +2,500 | $22.40 | $56K | 51,580 |
Page 9 of 41 · 802 trades